The dual expansion simplifies transcriptomics workflows by combining faster regional turnaround with easier sample logistics
The acquisition aims to bolster Merck’s hematology portfolio with Terns’ lead oncology candidate, TERN-701
Capstan's lead asset, CPTX2309, is a targeted lipid nanoparticle (tLNP) that delivers an mRNA encoding an anti-CD19 chimeric antigen receptor (CAR) to CD8-expressing cytotoxic T cells in vivo
Hengrui Pharma has granted Merck exclusive rights to develop, manufacture and commercialize HRS-5346 worldwide, excluding Greater China region
CMG1A46 is an investigational T cell-engager with potential to deeply deplete uncontrolled B cells present in autoimmune diseases such as lupus
Sun Pharma has obtained rights from MSD to develop, manufacture and commercialise Tedizolid Phosphate in India
CN201 is a next generation CD3xCD19 bispecific antibody that augments and diversifies Merck’s pipeline, with potential applications in B-cell malignancies and autoimmune diseases
An investigational CYP11A1 Inhibitor, for the treatment of metastatic castration-resistant prostate cancer
Acquisition includes Restoret, a novel late-phase candidate for diabetic macular edema and neovascular age-related macular degeneration
Argo will receive upfront payments of US$ 185 million from Novartis and is eligible to receive potential option and milestone payments as well as tiered royalties on commercial sales.
Subscribe To Our Newsletter & Stay Updated
